Size-Dependent Effects of Gold Nanoparticles Uptake on Maturation and Antitumor Functions of Human Dendritic Cells In Vitro

Tomić, Sergej; Đokić, Jelena; Vasilijić, Saša; Ogrinc, Nina; Rudolf, Rebeka; Pelicon, Primož; Vučević, Dragana; Milosavljević, Petar; Janković, Srđa; Anžel, Ivan; Rajković, Jovana; Rupnik, Marjan Slak; Friedrich, Bernd; Čolić, Miodrag

doi:10.1371/journal.pone.0096584

Cited by 122 publications

(100 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL-10 is produced by various cell subsets, including Tregs and phagocytic cells (Ouyang et al 2011). Our previous paper showed that gold nanoparticles acted down-modulatory on the immune response by increasing the production of IL-10 and subsequent down-regulation of IL-12 and IL-23 by dendritic cells (Tomic et al 2014), which are Th1-and Th17-inducing cytokines, respectively (Č olić et al 2009;Zhu et al 2010). Such mechanisms may also be involved in tolerance induction by CNFs, which is the aim of our ongoing study.…”

Section: Discussionmentioning

confidence: 99%

Cytocompatibility and immunomodulatory properties of wood based nanofibrillated cellulose

et al. 2014

Self Cite

View full text Add to dashboard Cite

Cellulose nanofibrils (CNFs), unique and promising natural materials have gained significant attention recently for biomedical applications, due to their special biomechanical characteristics, surface chemistry, good biocompatibility and low toxicity. However, their long bio-persistence in the organism may provoke immune reactions and this aspect of CNFs has not been studied to date. Therefore, the aim of this work was to examine and compare the cytocompatibility and immunomodulatory properties of CNFs in vitro. CNFs (diameters of 10-70 nm; lengths of a few microns) were prepared from Norway spruce (Picea abies) by mechanical fibrillation and high pressure homogenisation. L929 cells, rat thymocytes or human peripheral blood mononuclear cells (PBMNCs) were cultivated with CNFs. None of the six concentrations of CNFs (31.25 µg/ml-1 mg/ml) induced cytotoxicity and oxidative stress in the L929 cells, nor induced necrosis and apoptosis of thymocytes and PBMNCs. Higher concentrations (250 µg/ml-1 mg/ml) slightly inhibited the metabolic activities of the L929 cells as a consequence of inhibited proliferation. The same concentrations of CNFs suppressed the proliferation of PBMNCs to phytohemaglutinine, a T-cell mitogen, and the process was followed by down-regulation of interleukin-2 (IL-2) and interferon-γ production. The highest concentration of CNFs inhibited IL-17A, but increased IL-10 and IL-6 production. The secretion of pro-inflammatory cytokines, IL-1β and tumor necrosis factor-α as well as Th2 cytokine (IL-4), remained unaltered. In conclusion, the results suggest that these CNFs are cytocompatible nanomaterial, according to current ISO criteria, with non-inflammatory and nonimmunogenic properties. Higher concentrations seem to be tolerogenic to the immune system, a characteristic very desirable for implantable biomaterials.

show abstract

Section: Discussionmentioning

confidence: 99%

Cytocompatibility and immunomodulatory properties of wood based nanofibrillated cellulose

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previous uses of colloidal gold in treatment of arthritis have been largely surpassed by more effective drugs with fewer side effects (71). This is likely due to the influence of gold nanoparticles on cell function (72) owing to their affinity for DNA. Different changes in gene expression have been shown for acute and chronic exposure to gold nanoparticles (73).…”

Section: Inorganic Nanoparticlesmentioning

confidence: 99%

Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date

et al. 2016

View full text Add to dashboard Cite

In this review we provide an up to date snapshot of nanomedicines either currently approved by the US FDA, or in the FDA clinical trials process. We define nanomedicines as therapeutic or imaging agents which comprise a nanoparticle in order to control the biodistribution, enhance the efficacy, or otherwise reduce toxicity of a drug or biologic. We identified 51 FDA-approved nanomedicines that met this definition and 77 products in clinical trials, with ~40% of trials listed in clinicaltrials.gov started in 2014 or 2015. While FDA approved materials are heavily weighted to polymeric, liposomal, and nanocrystal formulations, there is a trend towards the development of more complex materials comprising micelles, protein-based NPs, and also the emergence of a variety of inorganic and metallic particles in clinical trials. We then provide an overview of the different material categories represented in our search, highlighting nanomedicines that have either been recently approved, or are already in clinical trials. We conclude with some comments on future perspectives for nanomedicines, which we expect to include more actively-targeted materials, multi-functional materials ("theranostics") and more complicated materials that blur the boundaries of traditional material categories. A key challenge for researchers, industry, and regulators is how to classify new materials and what additional testing (e.g. safety and toxicity) is required before products become available.

show abstract

“…Čolić et al also reported that gold NPs of 10nm and 50nm were internalized predominantly via a clathrin/dynamin-dependent mechanism by DCs, and a significantly higher number of 10 nm AuNPs per cell were uptaken than 50 nm AuNPs. It was demonstrated that smaller AuNPs inhibit the maturation of LPS induced DCs more strongly than larger ones [30]. Similarly, silica-titania hollow nanoparticles with 50 nm diameter, compared with up to 125nm, generated more ROS (Figure 1.a), and exhibited the highest induction of inflammatory cytokines (IL-1, IL-6 and TNF-α) with mouse alveolar macrophage (J774.1) in vitro [31].…”

Section: Physicochemical Properties Of Nanoparticles Modulate Innamentioning

confidence: 99%

Effects of engineered nanoparticles on the innate immune system

Liu

Hardie

Zhang

et al. 2017

Seminars in Immunology

206

122

View full text Add to dashboard Cite

Engineered nanoparticles (NPs) have broad applications in industry and nanomedicine. When NPs enter the body, interactions with the immune system are unavoidable. The innate immune system, a non-specific first line of defense against potential threats to the host, immediately interacts with introduced NPs and generates complicated immune responses. Depending on their physicochemical properties, NPs can interact with cells and proteins to stimulate or suppress the innate immune response, and similarly activate or avoid the complement system. NPs size, shape, hydrophobicity and surface modification are the main factors that influence the interactions between NPs and the innate immune system. In this review, we will focus on recent reports about the relationship between the physicochemical properties of NPs and their innate immune response, and their applications in immunotherapy.

show abstract

Size-Dependent Effects of Gold Nanoparticles Uptake on Maturation and Antitumor Functions of Human Dendritic Cells In Vitro

Cited by 122 publications

References 59 publications

Cytocompatibility and immunomodulatory properties of wood based nanofibrillated cellulose

Cytocompatibility and immunomodulatory properties of wood based nanofibrillated cellulose

Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date

Effects of engineered nanoparticles on the innate immune system

Contact Info

Product

Resources

About